BioNeutra Global Corporation · TSXV:BGA
BioNeutra Global — Investor Presentation (March 2016)
22 slides from BioNeutra Global's investor presentation, Mar 16, 2016
Slide 1: Investor Presentation Winter 2016
TSX.V: BGA www.bioneutra.ca INVESTOR PRESENTATION WINTER | 2016
Slide 2: Forward Looking Statement
Forward Looking Statement In the interest of providing potential investors in BioNeutra Global Corporation (the “Company”) with information regarding the Company’s future plans and operations, certain statements and graphs throughout the presentation contains “forward-looking statements”. Forward-lo
Slide 3: Highlights
Highlights BioNeutra (TSX.V: BGA) researches, develops Went public in November and commercializes food ingredients for NUTRACEUTICAL & MAINSTREAM FOOD PRODUCTS. BioNeutra has a robust product pipeline to service a rapidly growing 2014 FUNCTIONAL FOODS INDUSTRY Their innovative product $15M and forec
Slide 4: Capital Structure (TSX.V: BGA)
Capital Structure (TSX.V: BGA) Symbol TSX.V: BGA 52 Week High/Low $0.60 – $0.40 Issued and Outstanding 45,819,787 Warrants and Options 6,200,000 Fully Diluted 44,280,204 Market Capitalization $27,491,872 Cash in Treasury $4,186,822 As of June 30, 2015 BioNeutra - Confidential 2016 www.bioneutra.ca 4
Slide 5: BioNeutra Global Corporation
BioNeutra Global Corporation BioNeutra researches, BioNeutra's patented The only company to develops and process naturally get approvals in North commercializes food transforms starch America and Europe ingredients for molecules from local for IMO nutraceutical and agriculture cereal crops mainstrea
Slide 6: Corporate Structure
Corporate Structure BioNeutra Offshore BioNeutra International BioNeutra North America BioNeutra Alberta Plants Production, Patents, IP, Since 2003 Operation, Since 2003 Plant Production 2015 Since 2010 BioNeutra Global Corporation November 5, 2014 Toronto CNSX: BGA December 9, 2015 TSX.V Listing Bu
Slide 7: Senior Management Team
Senior Management Team Jianhua Zhu | President /CEO In 2003, Dr. Zhu founded BioNeutra to research, develop and commercialize ingredients for functional and health foods, as well as nutraceuticals. The core business is centered on the patented production of VitaFiber™ IMO (isomalto-oligosaccharides)
Slide 8: VitaFiber: What it is and Key Health Benefits
• A mixture of a number • High percentage of • BioNeutra has spent of short chain alpha (1-6) glycosidic 10 years optimizing the What it is carbohydrates bonds which is digestion resistant manufacturing process to create the best possible product Key health benefits • Low glycemic response • Improve
Slide 9: Patented Manufacturing Process
Patented Manufacturing Process Raw Material: Starch (from Wheat, Potato, Corn, Tapioca….) Patented Enzymatic Transformation Process Fermentation Process Products: Isomalto-oligosaccharide Health sweetener Dietary soluble fiber Prebiotic ingredient Functional Food Ingredient Novel Food Ingredient Vit
Slide 10: IMO and Prebiotics
IMO and Prebiotics (VitaFiberTM) Colon Non-digestible and slowly digested foods or nutrients in upper digestive system: mouth, stomach and small intestine A prebiotic because it is consumed selectively by specific bacteria in the intestine (colon): recognized as “benefit” bacteria BioNeutra - Co
Slide 11: Emerging Markets Driving Demand
Emerging Markets Driving Demand BioNeutra - Confidential 2016 www.bioneutra.ca 11
Slide 12: Aggressive Growth Strategy
Aggressive Growth Strategy Focused on emerging markets as a strategic offset to developed market issues Positioned New product to grow Market and development w/ IP corporate alliances rights for global to and drive for overall local markets shareholder geographic benefits value Outsourcing of produc
Slide 13: VitaFiber Target Markets
VitaFiber™ Target Markets Lead Growth Emerging • Nutritional bars • Beverages • Calorie reduction • Meal replacements • Baking • Global markets • Dairy applications such as: • Middle East • Latin America • Africa • Eastern Europe • Asia BioNeutra - Confidential 2016 www.bioneutra.ca 13
Slide 14: Comparison to Other Products
Comparison to Other Products VitaFiberTM Inulin FOS Raw Material Starch Chicory Root Inulin, Sucrose Tolerability (g/day) 45 15 15 Calories (cal/g) 2.0 1.2 1.5 pH Stability 2-9 4-8 4-8 Natural 60% <10% 30% Sweetness BioNeutra - Confidential 2016 www.bioneutra.ca 14
Slide 15: VitaFiber Sales Revenue
VitaFiber™ Sales Revenue Revenue Projected Revenue Anticipate 20% Growth per year BioNeutra - Confidential 2016 www.bioneutra.ca 15
Slide 16: Amazon.com Sales
Amazon.com Sales Launched on Amazon.com March 3, 2015 VitaFiber™ More than sugar First 3 weeks 400,000 700 (powder) sweetener views on & basic syrup UNITS SOLD First reviews below: BioNeutra - Confidential 2016 www.bioneutra.ca 16
Slide 17: Product Pipeline
Product Pipeline CURRENT POWDER AND SYRUP PIPELINE (ESTIMATED) PRODUCTS (NON-GMO) • Sweet VitaFiberTM (2015/16) • VitaFiberTM – from corn starch − 100% as sweet as sugar, an all natural • VitaFiberTM – from Tapioca starch blended product • Organic Tapioca (August 2015) − In development − Powder and
Slide 18: 2014 Media Coverage
2014 Media Coverage BioNeutra was featured in many articles and online stories BioNeutra - Confidential 2016 www.bioneutra.ca 18
Slide 19: BioNeutra in the Spotlight
BioNeutra in the Spotlight BioNeutra was featured Dr. Jianhua Zhu receiving in the Edmonton Journal Earnst & Young Entrepreneur August 23, 2015 of the year award, Prairie Division http://www.edmontonjournal.com/BioNeutra+acquires+building+producti BioNeutra - Confidential on+facility/11314076/story.
Slide 20: Growth Timeline
Growth Timeline Approval expected in Australia/New Contract Zealand and manufacturer India FDA Expert in Indonesia and 2015: Panel Approval China Break Even Commercial (Marketing plant setting GFSI CFIA, FDA EFSA approval and Sales) up in Alberta expected Feasibility Application in European Union &
Slide 21: Why Invest in BioNeutra
Why Invest in BioNeutra • Strong growth in revenue and cash flow, with high profit margins • Recent acquisition of production facility to ensure quality control • Product leadership to support premium price and growing global demand • Management team who can execute BioNeutra - Confidential 2016 www
Slide 22: Contact
Contact BioNeutra Global Corporation Investor Relations 9608-25 AVE NW Mr. Bill Smith Edmonton, Alberta Chairman of the Board and T6N 1J4, Canada Senior Vice President T: +1 (780) 466.1481 T: +1 (780) 466.1481, ext. 117 F: +1 (780) 801.0036 Dr. Jianhua Zhu President and C.E.O. T: +1 (780) 466.1481,
BioNeutra Global — Investor Presentation (March 2016) on 6ix